Study of three drugs for recurrent ovarian, fallopian tube, or peritoneal cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two standard chemotherapy drugs, cyclophosphamide and bevacizumab, with or without an immunotherapy drug called envafolimab. It aims to see if adding envafolimab helps shrink tumors better in people whose cancer has come back after platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back after platinum-based chemotherapy.
- You have tumors that can be measured on a CT scan (at least 1 cm for non-lymph node spots or 1.5 cm for lymph nodes).
- Your daily activities are not severely limited (ECOG score 0 or 1).
- You have not been treated before with a PD-1/PD-L1 inhibitor (like envafolimab or similar drugs).
- You are not allergic to large protein drugs or any components of the study medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a combination of two drugs—liposomal irinotecan (a chemotherapy) and enlonstobart (an immune-boosting antibody)—for ovarian cancer that came back within 6 months of platinum-based chemotherapy. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This study tests a combination of two targeted drugs (mirvetuximab soravtansine and suvemcitug) for people with ovarian cancer that has come back after platinum-based chemotherapy and is no longer responding to it. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.